Diagnostic Value of a Group of MicroRNA Genes Hypermethylated in Ovarian Carcinoma


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The study was designed to determine genes of microRNAs hypermethylated in malignant ovarian tumors and to select new diagnostic and prognostic markers of the disease and effective system of markers. Using methyl-specific PCR and a representative sample of 54 ovarian cancer specimens, we determined 5 microRNA genes (MIR-34b/c, MIR-9-1, MIR-124-3, MIR-129-2, and MIR-107) hypermethylated in the majority of tumor samples in comparison with paired samples of histologically unchanged tissue (48-57% vs. 4-19%, p<0.001). Using ROC-analysis, we selected an effective system of 4 markers for diagnosis of ovarian cancer (MIR-9-1, MIR-124-3, MIR-129-2, and MIR-107) characterized by high sensitivity and specificity (up to 87-94% at AUC=0.92) relative to the conventional norm (54 paired samples of histologically unchanged tissue) and absolute norm (18 ovarian tissue samples from subjects who died from non-tumor diseases). It was also shown that methylation of MIR-129-2, MIR-9-1, and MIR-34b/c genes is significantly (p<0.01) correlated with the clinical stage or the presence of metastases. The results indicate that epigenetic modifications of the studied microRNA genes are involved in the pathogenesis and progression of ovarian cancer and attest to their diagnostic and prognostic potential.

About the authors

E. A. Braga

Research Institute of General Pathology and Pathophysiology; Research Center of medical Genetics

Author for correspondence.
Email: eleonora10_45@mail.ru
Russian Federation, Moscow; Moscow

V. I. Loginov

Research Institute of General Pathology and Pathophysiology; Research Center of medical Genetics

Email: eleonora10_45@mail.ru
Russian Federation, Moscow; Moscow

E. A. Filippova

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

A. M. Burdennyi

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

I. V. Pronina

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

T. P. Kazubskaya

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

D. S. Khodyrev

Federal Scientific and Clinical Center of Specialized Medical Assistance and Medical Technologies, Federal Medical and Biological Agency of the Russian Federation

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

D. O. Utkin

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

D. N. Kushlinskii

V. I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russian Federation

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

L. V. Adamyan

V. I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russian Federation

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

N. E. Kuslinskii

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2018 Springer Science+Business Media, LLC, part of Springer Nature